OneDigital Investment Advisors LLC Has $3.05 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

OneDigital Investment Advisors LLC decreased its stake in Edwards Lifesciences Co. (NYSE:EW) by 4.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,195 shares of the medical research company’s stock after selling 2,171 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $3,048,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Crewe Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth about $28,000. First Community Trust NA acquired a new position in Edwards Lifesciences in the second quarter valued at about $29,000. Webster Bank N. A. bought a new stake in Edwards Lifesciences during the second quarter worth about $39,000. Peoples Bank KS acquired a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $40,000. Finally, Versant Capital Management Inc raised its stake in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 326 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on EW. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price target on shares of Edwards Lifesciences in a report on Thursday, September 12th. The Goldman Sachs Group cut their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a report on Friday, July 26th. Evercore ISI decreased their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Royal Bank of Canada reduced their target price on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Finally, Daiwa Capital Markets raised shares of Edwards Lifesciences from a “neutral” rating to an “outperform” rating in a report on Wednesday, July 31st. Seventeen analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Stock Up 2.4 %

Shares of NYSE:EW opened at $67.76 on Friday. The company has a 50 day moving average price of $67.44 and a two-hundred day moving average price of $76.18. The company has a market capitalization of $39.96 billion, a PE ratio of 9.78, a PEG ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.59 EPS. Analysts forecast that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insider Activity

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 4.09 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total value of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 41,250 shares of company stock worth $2,744,438 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.